MA40027A - Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique - Google Patents

Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique

Info

Publication number
MA40027A
MA40027A MA040027A MA40027A MA40027A MA 40027 A MA40027 A MA 40027A MA 040027 A MA040027 A MA 040027A MA 40027 A MA40027 A MA 40027A MA 40027 A MA40027 A MA 40027A
Authority
MA
Morocco
Prior art keywords
agonist
beta
pharmaceutical composition
anticholinergic agent
anticholinergic
Prior art date
Application number
MA040027A
Other languages
English (en)
Inventor
Geena Malhotra
Preeti Raut
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of MA40027A publication Critical patent/MA40027A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques à inhaler qui comprennent un ou plusieurs bronchodilatateurs.
MA040027A 2014-06-18 2015-06-18 Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique MA40027A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1969MU2014 2014-06-18

Publications (1)

Publication Number Publication Date
MA40027A true MA40027A (fr) 2015-12-23

Family

ID=53762205

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040027A MA40027A (fr) 2014-06-18 2015-06-18 Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique

Country Status (6)

Country Link
US (1) US20170119744A1 (fr)
EP (1) EP3157567A1 (fr)
AU (1) AU2015275933A1 (fr)
CA (1) CA2952760A1 (fr)
MA (1) MA40027A (fr)
WO (1) WO2015193631A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3880169B1 (fr) * 2018-11-12 2025-07-23 Kindeva Drug Delivery L.P. Formulation d'umeclidinium et vilanterol et inhalateur
EP3996672A1 (fr) * 2019-07-12 2022-05-18 Kindeva Drug Delivery L.P. Formulation d'aérosol, cartouche et inhalateur contenant la formulation, et procédé d'utilisation
WO2021009573A1 (fr) * 2019-07-12 2021-01-21 Kindeva Drug Delivery L.P. Formulation d'aérosol, cartouche et inhalateur contenant la formulation, et procédé d'utilisation
CN120324388A (zh) * 2025-05-16 2025-07-18 山东京卫制药有限公司 一种吸入气雾剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
MX2010002781A (es) 2007-09-12 2010-04-01 Glaxo Group Ltd Combinacion novedosa de angentes terapeuticos.
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
KR20140041700A (ko) 2011-06-08 2014-04-04 글락소 그룹 리미티드 우메클리디늄을 포함하는 건조 분말 흡입기 조성물
US20140113888A1 (en) 2011-06-08 2014-04-24 Glaxo Group Limited Novel Combination of Therapeutic Agents
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
EP2668941A1 (fr) * 2012-05-31 2013-12-04 Almirall, S.A. Nouveau dosage et formulation d'abediterol
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
SI2968313T1 (en) * 2013-03-15 2018-05-31 Verona Pharma Plc Combination of medicines
EA201690302A1 (ru) 2013-07-30 2016-06-30 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Композиции для местного применения для лечения избыточного потоотделения и способы их применения

Also Published As

Publication number Publication date
WO2015193631A1 (fr) 2015-12-23
EP3157567A1 (fr) 2017-04-26
US20170119744A1 (en) 2017-05-04
AU2015275933A1 (en) 2017-02-02
CA2952760A1 (fr) 2015-12-23

Similar Documents

Publication Publication Date Title
IL271657A (en) medical preparation
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
PT3513809T (pt) Composição medicinal compreendendo tivozanib
GEP20217239B (en) Pharmaceutical composition
GB201608323D0 (en) Pharmaceutical compositions
GB201515387D0 (en) Compositions
WO2015120062A8 (fr) Composés et compositions thérapeutiques
EP3221341A4 (fr) Compositions à variant thérapeutique d'alpha-2-macroglobuline
GEP20217240B (en) Pharmaceutical composition
GB201705303D0 (en) Pharmaceutical compositions
GB201506526D0 (en) Medicinal composition
MX379126B (es) Formulación de factor viii.
MX371443B (es) Composiciones farmaceuticas que comprenden levocetirizina.
GB201705304D0 (en) Pharmaceutical compositions
SG11202001179YA (en) Pharmaceutical compositions
GB201705306D0 (en) Pharmaceutical compositions
GB201705305D0 (en) Pharmaceutical compositions
MY188169A (en) Pharmaceutical compositions and use thereof
GB201615917D0 (en) Pharmaceutical composition
GB201615914D0 (en) Pharmaceutical composition
ZA202000014B (en) Pharmaceutical compositions
WO2015108945A3 (fr) Compositions et méthodes pour l'administration d'agents thérapeutiques
IL263999A (en) Pharmaceutical compositions
GB201616088D0 (en) Pharmaceutical composition
GB201615910D0 (en) Pharmaceutical composition